Foghorn Therapeutics (FHTX) Assets Average (2020 - 2026)

Foghorn Therapeutics' Assets Average history runs 7 years deep, the most recent figure standing at $210.1 million for Q1 2026.

• On a quarterly basis, Assets Average fell 22.56% year-over-year to $210.1 million in Q1 2026; TTM through Mar 2026 was $210.1 million, a 22.56% decrease from a year earlier, with the FY2025 full-year figure at $241.0 million, down 15.41% from the prior year.
• Assets Average improved to $210.1 million in Q1 2026 per FHTX's latest filing, from $201.5 million in the prior quarter.
• Across five years, Assets Average topped out at $504.0 million in Q1 2022 and bottomed at $201.5 million in Q4 2025.
• The 5-year median for Assets Average is $299.7 million (2023), against an average of $325.3 million.
• Across the five-year window, Assets Average soared 125.76% in 2022 and tumbled 32.3% in 2025, its largest moves.
• Year by year, Assets Average stood at $419.4 million in 2022, then decreased by 28.55% to $299.7 million in 2023, then retreated by 1.17% to $296.2 million in 2024, then plunged by 31.96% to $201.5 million in 2025, then grew by 4.27% to $210.1 million in 2026.
• Per Business Quant, the three latest FHTX Assets Average figures stand at $210.1 million (Q1 2026), $201.5 million (Q4 2025), and $215.6 million (Q3 2025).